All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CD276 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human CD276. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD276 antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of multiple myeloma.
CAR Construction : 8H9-4-1BB-CD3ζ Fig.1 Therapeutic effects of B7-H3 CAR-T cells in tumor xenografts. Tumor growth in A549-injected mice (b) or HCT 116-injected mice (c) was measured using digital caliper, and tumor area was calculated. Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., ... & Zhao, Q. (2021). Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of hematology & oncology, 14(1), 1-18. |
CAR Construction : 8H9-4-1BB-CD3ζ Fig.2 Cytokine production in B7-H3 CAR and vehicle T cells. Effector T cells were incubated with target A549 or HCT 116 cells at a ratio of 10:1 for 24 h. The concentrations of cytokines were measured using flow cytometry. Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., ... & Zhao, Q. (2021). Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of hematology & oncology, 14(1), 1-18. |
CAR Construction : 8H9-4-1BB-CD3ζ Fig.3 Memory cell phenotypes of B7-H3 CAR-T cells. Expression of CD62L and CCR7 on T cells was identified with staining with anti-CD62L and anti-CCR7 antibodies, respectively, and measured using flow cytometry. Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., ... & Zhao, Q. (2021). Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of hematology & oncology, 14(1), 1-18. |
CAR Construction : 8H9-4-1BB-CD3ζ Fig.4 Degranulation markers in B7-H3 CAR T cells. Expressions of CD107a, intracellular granzyme B and perforin staining on T cells were stained with anti CD107a, granzyme B and perforin antibodies and measured by flow cytometry. Liu, J., Yang, S., Cao, B., Zhou, G., Zhang, F., Wang, Y., ... & Zhao, Q. (2021). Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Journal of hematology & oncology, 14(1), 1-18. |
CAR Construction : Fig.5 The binding ability of anti-B7-H3 mAb. Binding kinetics of anti-B7-H3 antibody ch8H9 to (2Ig-B7-H3-Fc WT, R127A, and D128A) by surface plasmon resonance. Ahmed, M., Cheng, M., Zhao, Q., Goldgur, Y., Cheal, S. M., Guo, H. F., ... & Cheung, N. K. V. (2015). Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. Journal of Biological Chemistry, 290(50), 30018-30029. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CD276 (CBFYC-1202) h(CD28-CD3ζ) CAR, pCDCAR1 (CAR-WFY5980). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION